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Background: Cryptococcus gattii has been the cause of an ongoing outbreak starting in 1999 on Vancouver Island,
British Columbia and spreading to mainland Canada and the US Pacific Northwest. In the course of the outbreak,
C. gattii has been identified outside of its previously documented climate, habitat, and host disease. Genotyping of
C. gattii is essential to understand the ecological and geographical expansion of this emerging pathogen.
Methods: We developed and validated a mismatch amplification mutation assay (MAMA) real-time PCR panel for
genotyping C. gattii molecular types VGI-VGIV and VGII subtypes a,b,c. Subtype assays were designed based on
whole-genome sequence of 20 C. gattii strains. Publically available multilocus sequence typing (MLST) data from a
study of 202 strains was used for the molecular type (VGI-VGIV) assay design. All assays were validated across DNA
from 112 strains of diverse international origin and sample types, including animal, environmental and human.
Results: Validation revealed each assay on the panel is 100% sensitive, specific and concordant with MLST. The
assay panel can detect down to 0.5 picograms of template DNA.
Conclusions: The (MAMA) real-time PCR panel for C. gattii accurately typed a collection of 112 diverse strains and
demonstrated high sensitivity. This is a time and cost efficient method of genotyping C. gattii best suited for
application in large-scale epidemiological studies.
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Cryptococcosis, a potentially fatal fungal disease, has pri-
marily been observed in immune-compromised individuals
and mainly associated with Cryptococcus neoformans infec-
tion. It is now recognized that Cryptococcus gattii, once
considered to be a variety of the Cryptococcus neoformans
complex, is also capable of causing serious disease in im-
munocompetent individuals and animals [1,2]. C. gattii has
been associated with a number of tree species in tropical
and subtropical regions [3]. More recently, C. gattii caused
an outbreak that began in 1999 on Vancouver Island,
British Columbia and has spread to mainland Canada
and the US Pacific Northwest [4]. This outbreak is unique
in that it marked the identification of a Cryptococcus* Correspondence: ekelley@tgen.org
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unless otherwise stated.species in a new climatic region (from tropical to temper-
ate), habitat (from tropical trees to temperate; e.g.,
Douglas Fir) and host disease (from primary neurologic
to primary pulmonary) [3,5].
Recent epidemiological studies of C. gattii in North
America provide insight into the organism’s geographical
expansion as well as the distribution of molecular geno-
types [6-9]. C. gattii has been classically classified into four
molecular types by MLST/AFLP, VGI/AFLP4, VGII/AFLP6,
VGIII/AFLP5, VGIV/AFLP7 [3,5], with additional molecu-
lar types recently identified [10]. Interestingly, molecular
types have been associated with significant differences in
disease type [3,5], antifungal susceptibilities [3,5,10], and se-
verity and outcome [3,5].
Contemporary methods for genotyping C. gattii are
PCR-restriction fragment length polymorphism (PCR-
RFLP), amplified fragment length polymorphism (AFLP),
multilocus microsatellite typing (MLMT), multilocus se-
quence typing (MLST), and most recent, matrix-assistedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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etry (MALDI-TOF MS) [11-14]. High resolution melting
(HRM) is a method that has been used to identify the Cryp-
tococcus neoformans-Cryptococcus gattii complex, though it
has not been employed for genotyping within either species
[15]. PCR-RFLP and AFLP require extensive lab work in-
volving restriction enzyme digestion and gel electrophoresis
[11]. Results are based on interpretation of gel electrophor-
esis profiles and as such, are not readily transferred or ana-
lyzed between laboratories. MLST, which requires DNA
sequencing of seven housekeeping genes, is the preferred
genotyping method for C. gattii and is easily transferrable
between laboratories [16]. MLMT allows for finer genotype
resolution than MLSTand has high reproducibility between
laboratories [14]. In some laboratories, real-time PCR is a
preferable option to methods involving DNA sequencing
(MLMT and MLST), which require either out-sourcing
to a sequencing capable laboratory or investment in,
and the maintenance of, an in-house instrument. Although
MALDI-TOF MS shows promise as a new genotyping
method, instrumentation is expensive and thus prohibitive
for many public health laboratories. Conversely, real-time
PCR instruments are becoming ubiquitous, easily main-
tained, and the use of unlabeled primers and no probe
makes reagents inexpensive [17]. Therefore, real-time PCR
is an accessible and increasing popular technology for
widespread molecular epidemiological efforts.
Here, we present a panel of real-time PCR assays, based
on mismatch amplification mutation assay (MAMA) meth-
odology, for rapid and sensitive molecular genotyping
of Cryptococcus gattii molecular types (VGI-VGIV) and
the dominant North American VGII subtypes (VGIIa-c)
[18,19]. MAMA, a form of allele-specific PCR (ASPCR),
employs primers that are designed for SNP genotyping. We
use known MLST sequences for the VGI-VGIV molecular
type assay design and whole genome sequences of 20




MAMA primers have an intentional penultimate mis-
match nucleotide at the 3′ end; the ultimate base is al-
ways the SNP assay target and is a perfect match for the
target SNP [18]. Mismatches decrease the efficiency of
primer extension by Taq polymerase, such that if two
mismatches are found together under the 3′ end of the
primer, the efficiency of the PCR is significantly reduced.
However, if a single mismatch at the penultimate base is
present, extension occurs from the 3′ matched base, and
efficiency of the PCR remains relatively high. Costly
fluorogenic oligonucleotide probes are not needed to
discriminate SNPs with this method. This discriminatory
design results in a cost-efficient, powerful and simplemethod of SNP genotyping [17,21]. Separate PCR reac-
tions are performed with a MAMA primer specific for
only one of the two target SNPs and with one universal
primer for amplification from the alternate direction.
Comparison of cycle threshold (Ct) values will reveal
which reaction is more efficient (has the smaller Ct
value). The more efficient reaction corresponds to the
SNP that is present in the sample.
MAMA design for MLST groups VGI, VGII, VGIII, and VGIV
The MLST SYBR MAMA design was informed by
MLST data collected for 202 C. gatii strains from a
worldwide collection [20]. The MLST library included
sequences from 77, 75, 26, and 24 isolates of the VGI,
VGII, VGIII, VGIV molecular types, respectively. The gene
encoding mannitol-1-phosphate dehydrogenase (MPD1)
was selected as the best candidate for assay design based
on its sequence conservation within each of the four
molecular types that allowed for design of assay primers
with a minimum number of degenerate bases. All 15 of
the known MPD1 allele sequences were aligned with
SeqMan Pro v.9.0.4 (DNASTAR, Madison, WI). SNPs
specific for each of the molecular types were identified
in the sequence alignment. MAMA primers were manu-
ally designed in Primer Express 3.0 (Life Technologies,
Carlsbad, CA) software with optimal mismatches chosen
as suggested by Li et. al. [19] (Table 1).
MAMA design for VGIIa, VGIIb, and VGIIc subtypes
Whole genome sequence typing (WGST) analysis of 20
C. gattii strains from a previous study revealed canonical
SNPs specific for each of the VGII a, b and c subtypes
(n = 2720, 3547, and 3819, respectively) [9]. In order to
minimize interference of adjacent mutations with primer
design, the genotype-specific SNPs were sorted according
to nearest neighboring mismatch within the sequence
alignment; in short, the SNPs with the most-conserved
flanking regions were the top candidates for assay design.
Sequence from the R265 strain reference genome [Gen-
Bank: CH408164] [2] surrounding the genotype-specific
SNPs was used for assay design. SYBR MAMA primers
were designed using the same criteria as previously de-
scribed for the MLST MAMA (Table 1).
Isolate selection
Initially, assays were validated with genomic DNA ex-
tracted from 57 C. gattii strains of North American ori-
gin and some historical isolates. The panel of isolates
including: 13 VGIIa, 4 VGIIb, and 24 VGIIc, and 8 each
of VGI and VGIII, was analyzed using each of the assays
(Table 2). All DNAs were genotyped by MLST prior to
screening. Further validation of the assays was accom-
plished by employing a more diverse isolate collection of
55 strains including isolates of international origin; this
Table 1 MAMA real-time PCR assay sequences and targets for genotyping C. gattii




Universal Primer sequence 5′ – > 3′ Match MAMA Primer sequence 5′ –> 3′ Mismatch MAMA Primer sequence 5′ –> 3′
VGI VGI-MPD471 MPD1 (471) G/A AGACTGTCCCAATGTCAAGCTTTC GCCTTGTATGTGGTAACACCAGTG GWGCCTTGTATGTGGTAACACCAGTA
VGII VGII-MPD495 MPD1 (495) T/A AGACTGTCCCAATGTCAAGCTTTC ATTAACCTTAGTGTTGGAGACCTTGACT AACCTTAGTGTTGGAGACCTTGACA
VGIIa VGIIa-45211 hypothetical protein A/C CCCAGCAACCTTGATCTGGA AGCTGCTCTAAGAGACACATCATCA AGCTGCTCTAAGAGACACATCATCC
VGIIb VGIIb-502129 not annotated G/A AATCGCTCGTCCTCATATGACA GTAGGCGGTGGGATAAGGTG GGTAGGCGGTGGGATAAGGTA
VGIIc VGIIc-257655 non-coding region C/T CGTTAATTTGGTTGTTTGACAACCT AGCAACTCACGCAGAAACAGAC GAGCAACTCACGCAGAAACAGAT
VGIII VGIII-MPD198 MPD1 (198) T/A TGACATTGGGACAGTCTGCAAT ACTGCTGCTTCTCCCGTTGT CTGCTGCTTCTCCCGTTGA


















Table 2 C. gattii strains for initial assay validation
Isolate ID MLST Year Geographic origin Source
B7488 VGI 2009 Oregon Human
B7496 VGI 2009 Hawaii Dolphin
B8551 VGI 2010 Oregon Human
B8852 VGI 2010 Oregon Human
B8886 VGI 2010 Oregon Soil
B8887 VGI 2010 Oregon Soil
B8990 VGI 2010 California Human
B9009 VGI 2011 Washington Human
B6864 VGIIa 2004 Oregon Human
B7395 VGIIa 2008 Washington Dog
B7422 VGIIa 2009 Oregon Cat
B7436 VGIIa 2009 California Alpaca
B7467 VGIIa 2009 Oregon Porpoise
B8555 VGIIa 2006 Washington Human
B8577 VGIIa 2009 British Columbia Soil
B8793 VGIIa 2010 Oregon Canine
B8849 VGIIa 2010 Oregon Environmental
CA-1014 VGIIa unknown California Human
CBS-7750 VGIIa 1990 California Environmental
ICB-107 VGIIa unknown Brazil Human
NIH-444 VGIIa 1972 Washington Human
B7394 VGIIb 2008 Washington Cat
B7735 VGIIb 2009 Oregon Human
B8554 VGIIb 2010 Oregon Dog
B8828 VGIIb 2010 Washington Porpoise
B6863 VGIIc 2005 Oregon Human
B7390 VGIIc 2008 Idaho Human
B7432 VGIIc 2009 Oregon Human
B7434 VGIIc 2008 Oregon Human
B7466 VGIIc 2008 Oregon Cat
B7491 VGIIc 2009 Oregon Human
B7493 VGIIc 2009 Oregon Sheep
B7641 VGIIc 2008 Oregon Cat
B7737 VGIIc 2009 Oregon Human
B7765 VGIIc 2009 Oregon Dog
B8210 VGIIc 2008 Oregon Human
B8214 VGIIc 2009 Oregon Human
B8510 VGIIc 2009 Oregon Human
B8549 VGIIc unknown Oregon Human
B8552 VGIIc unknown Oregon Human
B8571 VGIIc 2009 Washington Human
B8788 VGIIc 2010 Oregon Human
B8798 VGIIc 2005 Oregon Human
B8821 VGIIc 2010 Oregon Human
B8825 VGIIc 2009 Oregon Human
B8833 VGIIc 2010 Oregon Cat
B8838 VGIIc 2010 Washington Human
Table 2 C. gattii strains for initial assay validation
(Continued)
B8843 VGIIc 2010 Oregon Human
B8853 VGIIc 2010 Oregon Cat
B7415 VGIII 2009 California Alpaca
B7495 VGIII 2009 California Human
B8212 VGIII 2007 Oregon Human
B8260 VGIII 2009 Washington Cat
B8262 VGIII 1992 California Human
B8516/B8616 VGIII 2009 Oregon Cat
B9143 VGIII 2011 California Human
B9146 VGIII 2011 California Human
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VGIIc, 8 VGIII, and 10 VGIV molecular types (Table 3).
The strains came from a variety of environmental, human
and animal sources, including cats, a dog, an alpaca, a por-
poise, a sheep and a cow.
Isolate culturing and DNA extraction
Isolates were grown on Yeast Peptone Glucose (YPD)
agar plus 0.5% NaCl at 37°C for 24 hours; and DNA was
prepared using an UltraClean DNA Isolation Kit as de-
scribed by the manufacturer, with some modifications
(MO BIO Laboratories, Carlsbad, CA). Briefly, ~0.5 grams
of microbial cells were suspended in lysis solution in a
MicroBead tube and heated to 65°C for 15 minutes to in-
crease lysis efficiency. The MicroBead tube was then se-
cured horizontally using the MO BIO vortex adapter tube
holder (MO BIO Laboratories, Carlsbad, CA) and vortexed
at maximum speed for 10 minutes; post cell lysis, micro-
tubes were immediately placed on ice for 5 minutes. After
the lysis steps, DNA extraction was completed per manu-
facturer’s instructions. DNA was stored at −20°C.
Real-time PCR
Real-time PCR was performed on the ABI 7900HT real-
time PCR System (Life Technologies, Carlsbad, CA). Re-
actions for both perfect match and mismatch primer sets
were conducted in separate wells of a 384-well optical
plate, and reactions for each primer set were run in trip-
licate. Reactions were 10 μL total volume composed of
1X Platinum SYBR Green qPCR SuperMix-UDG with
ROX (Invitrogen, Grand Island, NY), 200 nM each of for-
ward and reverse primers, and 1 μL DNA extract (diluted
1:10). Reactions were incubated for 3 min at 50°C for
UDG digest followed by 3 min at 95°C for Taq polymerase
activation. PCR consisted of 45 cycles of 15 s at 95°C for
denaturation followed by 1 min at 60°C annealing and ex-
tension. Dissociation of PCR product was performed for
15 sec at 95°C, 15 sec at 60°C and 15 sec at 95°C as a qual-
ity assurance step to inspect reactions for primer-dimer.
Table 3 C. gattii strains for additional assay validation
Culture collection ID Geographic origin Sample type MLST Year of isolation
B4501 Australia Human VGI unknown
B4503 Australia Human VGI unknown
B4504 Australia Human VGI unknown
B4516 Australia Human VGI unknown
B5765 India Environmental VGI unknown
B9018 California Human VGI 2011
B9019 New Mexico Human VGI 2011
B9021 Rhode Island Human VGI 2011
B9142 Georgia Human VGI 2011
B9149 California Human VGI 2011
B8508 Oregon Human VGIIa 2009
B8512 Oregon Alpaca VGIIa 2009
B8558 Washington Human VGIIa 2010
B8561 Washington Human VGIIa 2010
B8563 Washington Human VGIIa 2010
B8567 Washington Dog VGIIa 2010
B8854 Washington Human VGIIa 2010
B8889 Oregon Environmental VGIIa 2010
B9077 Washington Environmental VGIIa 2011
B9296 British Columbia Environmental VGIIa 2011
B8211 Oregon Human VGIIb 2009
B8966 Oregon Horse VGIIb 2010
B9076 Washington Environmental VGIIb 2011
B9157 Washington Horse VGIIb 2011
B9170 Washington Porpoise VGIIb 2011
B9234 Washington Cat VGIIb 2011
B9290 British Columbia Cat VGIIb 2011
B9241 Oregon Human VGIIb 2011
B9428 Washington Cat VGIIb 2012
B9159 Washington Sheep VGIIc 2011
B9227 Oregon Cat VGIIc 2011
B9235 Oregon Human VGIIc 2011
B9244 Oregon Human VGIIc 2011
B9245 Oregon Human VGIIc 2011
B9295 British Columbia Environmental VGIIc 2011
B9302 Oregon Environmental VGIIc 2011
B9374 Oregon Human VGIIc 2011
B8965 New Mexico Human VGIII 2010
B9148 California Human VGIII 2011
B9151 Michigan Human VGIII 2011
B9163 New Mexico Human VGIII 2011
B9237 New Mexico Cat VGIII 2011
B9372 California Cow VGIII 2011
B9422 Oregon Cat VGIII 2012
B9430 Alaska Cat VGIII 2012
B7238 Botswana Human VGIV 2005
B7240 Botswana Human VGIV 2005
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Table 3 C. gattii strains for additional assay validation (Continued)
B7243 Botswana Human VGIV 2005
B7247 Botswana Human VGIV 2005
B7249 Botswana Human VGIV 2005
B7260 Botswana Human VGIV 2006
B7262 Botswana Human VGIV 2006
B7263 Botswana Human VGIV 2006
B7264 Botswana Human VGIV 2006
B7265 Botswana Human VGIV 2006
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rather to ensure amplification was specific for the targeted
sequence and to preclude non-specific amplification asso-
ciated with the ability of SYBR Green chemistry to bind
any double-stranded DNA. Data were analyzed in Se-
quence Detection Systems 2.3 software (Life Technologies,
Carlsbad, CA) for calculation of cycle threshold (Ct)
values and interpretation of dissociation curves.
For MAMA results, the perfect match primer set will
amplify earlier and yield the lowest Ct value, correspond-
ing to the SNP genotype of the isolate; secondary delayed
amplification plots with a higher Ct value, if present, are
due to mismatch priming (Figure 1). An algorithm for
genotype calling was implemented to expedite data ana-
lysis. The delta Ct value was calculated by subtracting the
match primer mean Ct from the mismatch primer mean
Ct. If the mismatch priming fails to yield a Ct value be-
cause it is beyond the instrument range, a Ct value = 40 is
assigned in order to calculate a ΔCt.







Figure 1 VGIIb MAMA plots with VGII DNA show the specificity of VG
DNA efficiently and yield a lower Ct value than the VGIIb mismatch primer
amplify VGIIa DNA more efficiently than the VGIIb match primers, resulting
DNA more efficiently than the VGIIb match primers, again resulting in a noA negative ΔCt value indicates a mismatch allele, whereas a
positive ΔCt indicates a match allele. A stringent threshold of
|ΔCt|≥ 3.3, approximately equivalent to one log10 difference
in the dynamic range, was established to ensure accuracy of
allele calls. If |ΔCt| < 3.3 is below the stringent threshold, this
could result in an inaccurate genotype call. In this case, it is
advisable to re-screen the sample across the failed assays.
Sensitivity and specificity of the assay panel were cal-
culated as well as concordance with the known MLST type
as determined by sequencing the MLST house keeping
genes. Assay repeatability and reproducibility were tested
by screening nine replicate reactions with the matching
primer sets and DNA for each assay on three separate days.
The lower limit of detection for each assay and its match-
ing template pair was tested. Each matching template and
assay pair was tested using six log10 serial dilutions of a sin-
gle template DNA, starting with 0.5 ng/μl. Template DNA
was quantified in triplicate by NanoDrop 3300 fluorospect-
rometer (NanoDrop Technologies, Wilmington, DE) using
Quant-iT PicoGreen dsDNA Reagent (Life Technologies,







IIb MAMA for VGIIb DNA. (A) The VGIIb match primers amplify VGIIb
s, resulting in a VGIIb genotype call. (B) The VGIIb mismatch primers
in a non-VGIIb genotype call. (C) VGIIb mismatch primers amplify VGIIc
n-VGIIb genotype call.
Table 4 MLST SYBR MAMA Ct values and genotype assignments for VGI-VGIV
VGI_MPD471 VGII_MPD495 VGIII_MPD198 VGIV_MPD423




























B7488 VGI 17.0 29.0 11.9 VGI 37.4 17.7 −19.7 non-VGII 28.4 14.9 −13.5 non-VGIII 32.4 16.3 −16.1 non-VGIV VGI
B7496 VGI 18.2 28.0 9.8 VGI 35.3 19.0 −16.3 non-VGII 24.5 16.4 −8.1 non-VGIII 31.7 17.9 −13.8 non-VGIV VGI
B8551 VGI 17.3 29.6 12.3 VGI 36.2 17.9 −18.3 non-VGII 28.7 15.3 −13.4 non-VGIII 39.0 16.7 −22.3 non-VGIV VGI
B8852 VGI 21.1 30.9 9.8 VGI 36.5 21.9 −14.6 non-VGII 27.8 19.1 −8.8 non-VGIII 32.0 20.6 −11.4 non-VGIV VGI
B8886 VGI 18.9 29.2 10.3 VGI 38.1 19.3 −18.8 non-VGII 26.7 16.4 −10.3 non-VGIII 32.3 17.9 −14.4 non-VGIV VGI
B8887 VGI 15.9 28.3 12.4 VGI 23.6 15.5 −8.1 non-VGII 33.6 16.2 −17.4 non-VGIII 34.1 15.5 −18.7 non-VGIV VGI
B8990 VGI 18.8 30.9 12.1 VGI 37.2 20.1 −17.1 non-VGII 31.3 16.9 −14.3 non-VGIII 40.0 19.3 −20.7 non-VGIV VGI
B9009 VGI 21.6 31.0 9.4 VGI 36.5 23.1 −13.4 non-VGII 28.6 19.4 −9.2 non-VGIII 40.0 21.1 −18.9 non-VGIV VGI
B4501 VGI 16.1 26.7 10.6 VGI 30.5 18.1 −12.4 non-VGII 30.6 17.3 −13.3 non-VGIII 29.4 16.4 −13.0 non-VGIV VGI
B4503 VGI 15.9 27.2 11.2 VGI 32.7 18.6 −14.1 non-VGII 33.8 17.9 −15.9 non-VGIII 28.7 16.1 −12.6 non-VGIV VGI
B4504 VGI 15.6 27.2 11.5 VGI 33.1 18.1 −15.1 non-VGII 33.9 17.4 −16.4 non-VGIII 28.7 15.8 −13.0 non-VGIV VGI
B4516 VGI 15.3 26.8 11.5 VGI 31.5 17.6 −13.9 non-VGII 33.4 16.8 −16.6 non-VGIII 29.7 15.3 −14.3 non-VGIV VGI
B5765 VGI 17.2 28.0 10.8 VGI 32.8 19.7 −13.0 non-VGII 34.4 19.2 −15.2 non-VGIII 29.0 16.3 −12.7 non-VGIV VGI
B9018 VGI 17.7 30.0 12.3 VGI 34.6 17.9 −16.7 non-VGII 31.8 18.6 −13.2 non-VGIII 35.0 18.3 −16.8 non-VGIV VGI
B9019 VGI 16.9 26.1 9.2 VGI 35.4 16.7 −18.7 non-VGII 34.9 16.7 −18.2 non-VGIII 30.5 16.8 −13.7 non-VGIV VGI
B9021 VGI 21.4 32.9 11.5 VGI 33.4 19.9 −13.5 non-VGII 32.7 20.5 −12.2 non-VGIII 35.5 20.4 −15.2 non-VGIV VGI
B9142 VGI 16.0 26.3 10.3 VGI 27.8 15.9 −11.9 non-VGII 32.7 16.5 −16.2 non-VGIII 31.7 16.6 −15.1 non-VGIV VGI
B9149 VGI 17.7 26.8 9.1 VGI 28.5 17.5 −11.0 non-VGII 28.5 18.2 −10.3 non-VGIII 31.0 18.3 −12.6 non-VGIV VGI
B6864 VGIIa 27.8 17.5 −10.3 non-VGI 19.3 33.1 13.8 VGII 34.7 19.7 −15.0 non-VGIII 40.0 16.1 −23.9 non-VGIV VGII
B7395 VGIIa 28.9 18.8 −10.1 non-VGI 21.3 32.6 11.3 VGII 40.0 19.2 19.2 non-VGIII 40.0 18.8 −21.2 non-VGIV VGII
B7422 VGIIa 27.4 17.4 −10.0 non-VGI 19.5 32.3 12.8 VGII 35.4 19.1 −16.3 non-VGIII 40.0 15.6 −24.4 non-VGIV VGII
B7436 VGIIa 27.8 17.9 −9.9 non-VGI 20.7 35.4 14.7 VGII 36.5 16.9 −19.6 non-VGIII 40.0 15.6 −24.4 non-VGIV VGII
B7467 VGIIa 30.9 20.7 −10.1 non-VGI 22.7 32.7 9.9 VGII 37.7 23.4 −14.2 non-VGIII 40.0 19.1 −20.9 non-VGIV VGII
B8555 VGIIa 27.9 17.7 −10.2 non-VGI 19.7 32.1 12.4 VGII 34.6 20.8 −13.8 non-VGIII 40.0 16.6 −23.4 non-VGIV VGII
B8577 VGIIa 31.1 20.9 −10.2 non-VGI 21.8 34.1 12.3 VGII 33.1 23.4 −9.8 non-VGIII 40.0 19.8 −20.2 non-VGIV VGII
B8793 VGIIa 27.4 17.4 −10.0 non-VGI 18.9 32.6 13.7 VGII 39.0 24.9 −14.1 non-VGIII 40.0 16.3 −23.7 non-VGIV VGII
B8849 VGIIa 28.9 18.7 −10.1 non-VGI 22.9 35.1 12.2 VGII 36.0 22.7 −13.3 non-VGIII 40.0 18.4 −21.6 non-VGIV VGII
CA-1014 VGIIa 20.4 11.6 −8.8 non-VGI 13.6 32.4 18.9 VGII 31.1 12.8 −18.3 non-VGIII 40.0 11.0 −29.0 non-VGIV VGII
CBS-7750 VGIIa 27.2 17.3 −9.9 non-VGI 18.8 33.1 14.3 VGII 38.0 25.5 −12.5 non-VGIII 40.0 15.8 −24.2 non-VGIV VGII
ICB-107 VGIIa 28.1 18.2 −9.9 non-VGI 20.0 34.7 14.8 VGII 37.5 25.4 −12.1 non-VGIII 40.0 15.6 −24.4 non-VGIV VGII
NIH-444 VGIIa 24.9 14.9 −10.0 non-VGI 17.0 33.2 16.2 VGII 34.9 17.7 −17.2 non-VGIII 40.0 13.3 −26.7 non-VGIV VGII
B8508 VGIIa 23.7 14.8 −8.9 non-VGI 17.4 30.4 13.0 VGII 34.5 16.2 −18.2 non-VGIII 29.1 14.9 −14.2 non-VGIV VGII


















Table 4 MLST SYBR MAMA Ct values and genotype assignments for VGI-VGIV (Continued)
B8558 VGIIa 22.5 13.7 −8.8 non-VGI 15.9 29.9 14.0 VGII 30.6 14.9 −15.7 non-VGIII 30.1 14.3 −15.9 non-VGIV VGII
B8561 VGIIa 26.5 17.7 −8.8 non-VGI 20.3 34.2 14.0 VGII 34.1 19.1 −15.0 non-VGIII 33.2 22.2 −11.0 non-VGIV VGII
B8563 VGIIa 24.4 16.0 −8.4 non-VGI 18.4 32.8 14.4 VGII 32.8 20.4 −12.4 non-VGIII 32.2 17.3 −14.9 non-VGIV VGII
B8567 VGIIa 25.6 17.0 −8.6 non-VGI 19.4 34.1 14.7 VGII 33.8 18.2 −15.6 non-VGIII 35.1 16.8 −18.2 non-VGIV VGII
B8854 VGIIa 24.7 15.8 −8.9 non-VGI 18.1 32.7 14.6 VGII 33.0 17.1 −15.9 non-VGIII 33.2 15.8 −17.4 non-VGIV VGII
B8889 VGIIa 28.0 17.6 −10.4 non-VGI 20.3 33.1 12.7 VGII 33.7 19.1 −14.6 non-VGIII 32.4 17.5 −15.0 non-VGIV VGII
B9077 VGIIa 33.6 17.8 −15.9 non-VGI 15.4 28.6 13.2 VGII 40.0 18.6 −21.5 non-VGIII 40.0 18.6 −21.4 non-VGIV VGII
B9296 VGIIa 27.3 19.8 −7.5 non-VGI 18.6 34.0 15.4 VGII 32.4 20.8 −11.6 non-VGIII 34.9 19.2 −15.7 non-VGIV VGII
B7394 VGIIb 31.9 22.5 −9.5 non-VGI 23.5 33.5 10.0 VGII 33.7 19.3 −14.4 non-VGIII 40.0 20.2 −19.8 non-VGIV VGII
B7735 VGIIb 26.9 17.8 −9.1 non-VGI 18.3 33.3 15.0 VGII 0.0 15.8 15.8 non-VGIII 40.0 15.4 −24.6 non-VGIV VGII
B8554 VGIIb 28.8 18.3 −10.5 non-VGI 20.8 32.2 11.3 VGII 35.5 22.0 −13.4 non-VGIII 40.0 18.3 −21.7 non-VGIV VGII
B8828 VGIIb 28.8 18.5 −10.3 non-VGI 20.7 32.7 11.9 VGII 35.9 19.2 −16.7 non-VGIII 40.0 31.9 −8.1 non-VGIV VGII
B8211 VGIIb 22.9 12.8 −10.1 non-VGI 15.1 30.1 15.1 VGII 33.0 13.9 −19.0 non-VGIII 33.8 12.9 −21.0 non-VGIV VGII
B8966 VGIIb 24.6 15.5 −9.0 non-VGI 17.3 25.9 8.6 VGII 29.3 15.6 −13.7 non-VGIII 28.9 14.7 −14.2 non-VGIV VGII
B9076 VGIIb 40.0 17.5 −22.5 non-VGI 17.1 27.5 10.5 VGII 40.0 18.4 −21.6 non-VGIII 30.6 18.0 −12.6 non-VGIV VGII
B9157 VGIIb 25.4 15.3 −10.2 non-VGI 17.6 29.4 11.9 VGII 31.2 16.1 −15.1 non-VGIII 31.6 16.1 −15.5 non-VGIV VGII
B9170 VGIIb 26.2 16.9 −9.3 non-VGI 17.5 28.7 11.2 VGII 29.5 17.6 −11.9 non-VGIII 31.1 17.7 −13.4 non-VGIV VGII
B9234 VGIIb 24.7 15.0 −9.6 non-VGI 15.4 30.3 14.9 VGII 30.2 15.7 −14.5 non-VGIII 33.3 15.8 −17.5 non-VGIV VGII
B9290 VGIIb 24.8 16.0 −8.8 non-VGI 15.9 34.1 18.2 VGII 30.6 20.8 −9.7 non-VGIII 33.2 16.6 −16.6 non-VGIV VGII
B9241 VGIIb 23.4 13.2 −10.3 non-VGI 15.5 28.0 12.5 VGII 30.0 13.9 −16.0 non-VGIII 34.0 13.5 −20.5 non-VGIV VGII
B9428 VGIIb 25.2 14.4 −10.7 non-VGI 18.7 28.3 9.6 VGII 30.2 15.5 −14.7 non-VGIII 34.1 15.0 −19.1 non-VGIV VGII
B6863 VGIIc 28.9 18.6 −10.2 non-VGI 20.7 34.2 13.5 VGII 33.2 22.7 −10.6 non-VGIII 40.0 18.1 −21.9 non-VGIV VGII
B7390 VGIIc 27.7 18.3 −9.5 non-VGI 19.9 33.9 13.9 VGII 39.5 24.7 −14.8 non-VGIII 40.0 16.9 −23.1 non-VGIV VGII
B7432 VGIIc 28.2 18.3 −9.9 non-VGI 20.0 32.6 12.7 VGII 34.8 18.0 −16.8 non-VGIII 40.0 17.2 −22.8 non-VGIV VGII
B7434 VGIIc 25.6 16.2 −9.4 non-VGI 17.7 34.5 16.8 VGII 34.4 17.9 −16.5 non-VGIII 40.0 13.8 −26.2 non-VGIV VGII
B7466 VGIIc 30.8 20.8 −10.0 non-VGI 22.4 33.6 11.2 VGII 37.4 23.7 −13.7 non-VGIII 40.0 19.5 −20.5 non-VGIV VGII
B7491 VGIIc 26.9 17.3 −9.6 non-VGI 19.2 33.0 13.8 VGII 0.0 16.8 16.8 non-VGIII 40.0 16.7 −23.3 non-VGIV VGII
B7493 VGIIc 27.1 17.4 −9.7 non-VGI 18.6 33.6 15.1 VGII 36.6 20.7 −15.8 non-VGIII 40.0 16.1 −23.9 non-VGIV VGII
B7641 VGIIc 26.0 17.3 −8.7 non-VGI 18.7 32.3 13.7 VGII 34.3 20.0 −14.3 non-VGIII 40.0 15.6 −24.4 non-VGIV VGII
B7737 VGIIc 28.0 18.5 −9.6 non-VGI 20.1 34.3 14.2 VGII 37.0 23.0 −14.0 non-VGIII 40.0 18.0 −22.0 non-VGIV VGII
B7765 VGIIc 22.5 13.0 −9.5 non-VGI 14.5 34.1 19.6 VGII 33.1 23.4 −9.7 non-VGIII 40.0 12.9 −27.1 non-VGIV VGII
B8210 VGIIc 27.8 18.1 −9.7 non-VGI 19.6 33.3 13.7 VGII 33.0 19.4 −13.5 non-VGIII 40.0 16.8 −23.2 non-VGIV VGII
B8214 VGIIc 27.1 17.7 −9.5 non-VGI 19.8 34.9 15.1 VGII 34.1 20.1 −14.0 non-VGIII 40.0 16.1 −23.9 non-VGIV VGII
B8510 VGIIc 26.8 17.6 −9.2 non-VGI 18.8 33.2 14.5 VGII 35.2 19.1 −16.1 non-VGIII 40.0 15.6 −24.4 non-VGIV VGII


















Table 4 MLST SYBR MAMA Ct values and genotype assignments for VGI-VGIV (Continued)
B8552 VGIIc 27.1 17.0 −10.1 non-VGI 18.6 33.2 14.6 VGII 34.3 19.7 −14.6 non-VGIII 40.0 16.6 −23.4 non-VGIV VGII
B8571 VGIIc 28.8 19.4 −9.4 non-VGI 21.5 33.4 11.9 VGII 34.5 22.8 −11.8 non-VGIII 40.0 19.5 −20.5 non-VGIV VGII
B8788 VGIIc 26.0 16.0 −10.0 non-VGI 18.5 29.5 11.0 VGII 38.0 20.4 −17.6 non-VGIII 40.0 16.6 −23.4 non-VGIV VGII
B8798 VGIIc 36.0 24.7 −11.4 non-VGI 26.5 33.3 6.8 VGII 37.2 19.2 −18.0 non-VGIII 40.0 22.5 −17.5 non-VGIV VGII
B8821 VGIIc 30.5 20.5 −10.0 non-VGI 22.3 33.0 10.7 VGII 37.0 29.0 −8.0 non-VGIII 40.0 18.7 −21.3 non-VGIV VGII
B8825 VGIIc 27.4 17.8 −9.6 non-VGI 19.6 33.7 14.1 VGII 36.0 20.5 −15.5 non-VGIII 40.0 17.5 −22.5 non-VGIV VGII
B8833 VGIIc 29.2 20.7 −8.6 non-VGI 19.5 33.4 13.9 VGII 35.4 19.6 −15.8 non-VGIII 40.0 15.5 −24.5 non-VGIV VGII
B8838 VGIIc 29.2 19.1 −10.1 non-VGI 21.5 32.8 11.3 VGII 32.9 22.3 −10.6 non-VGIII 40.0 18.5 −21.5 non-VGIV VGII
B8843 VGIIc 29.5 19.4 −10.1 non-VGI 21.5 33.7 12.2 VGII 37.5 22.1 −15.4 non-VGIII 40.0 19.1 −20.9 non-VGIV VGII
B8853 VGIIc 33.3 23.1 −10.2 non-VGI 24.8 33.7 8.9 VGII 34.2 27.8 −6.4 non-VGIII 40.0 21.5 −18.5 non-VGIV VGII
B9159 VGIIc 29.6 17.5 −12.1 non-VGI 19.1 29.9 10.7 VGII 40.0 26.0 −14.0 non-VGIII 40.0 18.0 −22.0 non-VGIV VGII
B9227 VGIIc 24.4 15.3 −9.1 non-VGI 15.5 28.1 12.6 VGII 27.9 16.1 −11.9 non-VGIII 31.0 16.3 −14.7 non-VGIV VGII
B9235 VGIIc 24.6 15.1 −9.5 non-VGI 15.3 28.9 13.7 VGII 29.2 16.4 −12.7 non-VGIII 31.2 15.9 −15.3 non-VGIV VGII
B9244 VGIIc 27.3 18.4 −8.9 non-VGI 18.5 31.8 13.3 VGII 28.2 21.0 −7.2 non-VGIII 30.6 18.8 −11.8 non-VGIV VGII
B9245 VGIIc 26.8 17.9 −8.9 non-VGI 18.0 33.5 15.5 VGII 31.2 19.3 −11.9 non-VGIII 34.2 18.5 −15.6 non-VGIV VGII
B9295 VGIIc 28.6 19.5 −9.1 non-VGI 19.9 40.0 20.1 VGII 33.6 25.5 −8.1 non-VGIII 34.4 20.3 −14.2 non-VGIV VGII
B9302 VGIIc 24.6 14.1 −10.5 non-VGI 16.9 26.7 9.8 VGII 28.8 15.1 −13.7 non-VGIII 31.5 14.1 −17.3 non-VGIV VGII
B9374 VGIIc 24.8 14.2 −10.6 non-VGI 18.2 27.3 9.1 VGII 29.1 15.2 −13.9 non-VGIII 32.8 14.4 −18.4 non-VGIV VGII
B7415 VGIII 26.8 15.9 −10.9 non-VGI 35.0 17.7 −17.3 non-VGII 12.4 27.1 14.7 VGIII 30.9 15.9 −15.0 non-VGIV VGIII
B7495 VGIII 28.1 18.0 −10.1 non-VGI 36.1 18.8 −17.3 non-VGII 14.1 30.1 16.0 VGIII 31.8 17.6 −14.2 non-VGIV VGIII
B8212 VGIII 26.0 15.7 −10.3 non-VGI 35.3 17.0 −18.3 non-VGII 12.4 28.5 16.1 VGIII 32.5 15.6 −16.9 non-VGIV VGIII
B8260 VGIII 29.6 19.6 −10.0 non-VGI 36.7 20.8 −15.9 non-VGII 15.9 30.7 14.8 VGIII 36.0 19.1 −16.9 non-VGIV VGIII
B8262 VGIII 27.2 17.2 −10.0 non-VGI 33.8 18.3 −15.5 non-VGII 13.5 30.0 16.4 VGIII 40.0 16.9 −23.1 non-VGIV VGIII
B8516/B8616 VGIII 28.4 18.5 −9.9 non-VGI 37.8 19.5 −18.3 non-VGII 14.6 29.1 14.5 VGIII 31.8 18.0 −13.8 non-VGIV VGIII
B9143 VGIII 28.6 18.3 −10.3 non-VGI 38.3 19.6 −18.7 non-VGII 14.5 30.2 15.7 VGIII 33.3 18.0 −15.3 non-VGIV VGIII
B9146 VGIII 30.3 19.5 −10.8 non-VGI 38.5 21.2 −17.3 non-VGII 15.8 30.1 14.3 VGIII 31.2 19.3 −11.9 non-VGIV VGIII
B8965 VGIII 26.2 16.8 −9.4 non-VGI 30.6 17.1 −13.5 non-VGII 16.1 30.6 14.5 VGIII 35.0 17.4 −17.6 non-VGIV VGIII
B9148 VGIII 26.0 16.6 −9.4 non-VGI 31.0 16.6 −14.4 non-VGII 15.9 30.6 14.7 VGIII 32.8 17.4 −15.4 non-VGIV VGIII
B9151 VGIII 25.7 16.5 −9.3 non-VGI 30.7 16.2 −14.4 non-VGII 15.4 30.3 14.9 VGIII 34.9 18.0 −17.0 non-VGIV VGIII
B9163 VGIII 26.9 17.5 −9.4 non-VGI 29.8 17.3 −12.5 non-VGII 16.9 29.7 12.8 VGIII 33.4 18.0 −15.4 non-VGIV VGIII
B9237 VGIII 26.7 17.9 −8.9 non-VGI 31.6 17.4 −14.2 non-VGII 17.3 35.0 17.7 VGIII 38.1 19.3 −18.9 non-VGIV VGIII
B9372 VGIII 23.5 12.7 −10.9 non-VGI 29.3 13.1 −16.1 non-VGII 14.8 27.4 12.6 VGIII 32.6 13.0 −19.6 non-VGIV VGIII
B9422 VGIII 23.9 12.8 −11.1 non-VGI 28.9 12.9 −15.9 non-VGII 14.6 26.8 12.2 VGIII 33.0 13.3 −19.7 non-VGIV VGIII
B9430 VGIII 23.5 12.9 −10.6 non-VGI 30.1 13.4 −16.8 non-VGII 15.1 28.5 13.4 VGIII 35.5 13.4 −22.0 non-VGIV VGIII


















Table 4 MLST SYBR MAMA Ct values and genotype assignments for VGI-VGIV (Continued)
B7240 VGIV 25.8 17.1 −8.8 non-VGI 33.9 19.5 −14.5 non-VGII 34.2 18.5 −15.7 non-VGIII 17.0 28.8 11.8 VGIV VGIV
B7243 VGIV 26.1 17.3 −8.8 non-VGI 32.0 19.6 −12.4 non-VGII 32.3 18.7 −13.6 non-VGIII 16.8 27.1 10.2 VGIV VGIV
B7247 VGIV 25.6 16.5 −9.1 non-VGI 33.4 19.2 −14.2 non-VGII 32.0 18.1 −13.9 non-VGIII 16.3 28.4 12.1 VGIV VGIV
B7249 VGIV 23.4 14.8 −8.6 non-VGI 31.6 16.7 −14.9 non-VGII 32.6 16.0 −16.6 non-VGIII 14.5 31.1 16.5 VGIV VGIV
B7260 VGIV 26.0 16.5 −9.4 non-VGI 30.9 18.0 −13.0 non-VGII 34.2 17.4 −16.8 non-VGIII 15.7 27.0 11.2 VGIV VGIV
B7262 VGIV 26.3 16.8 −9.5 non-VGI 31.4 18.7 −12.7 non-VGII 33.4 18.0 −15.4 non-VGIII 15.8 27.5 11.6 VGIV VGIV
B7263 VGIV 24.5 15.7 −8.9 non-VGI 33.1 17.9 −15.3 non-VGII 37.3 17.0 −20.3 non-VGIII 15.8 28.0 12.2 VGIV VGIV
B7264 VGIV 24.4 15.0 −9.4 non-VGI 31.2 16.9 −14.3 non-VGII 30.6 16.0 −14.6 non-VGIII 14.8 26.8 12.0 VGIV VGIV


















Table 5 VGII subtyping SYBR MAMA Ct values and genotype assignments for VGIIa,b,c
VGIIa_Assay_45211 VGIIb_Assay_502129 VGIIc_Assay_257655


















Delta Ct Type call
via assay
Final Call
B6864 VGIIa 17.2 30.5 13.3 VGIIa 31.0 17.5 −13.5 non-VGIIb 40.0 27.8 −12.2 non-VGIIc VGIIa
B7395 VGIIa 19.8 33.5 13.7 VGIIa 33.1 20.3 −12.9 non-VGIIb 40.0 30.6 −9.4 non-VGIIc VGIIa
B7422 VGIIa 18.3 33.6 15.4 VGIIa 26.4 17.6 −8.8 non-VGIIb 39.2 28.6 −10.6 non-VGIIc VGIIa
B7436 VGIIa 18.6 31.7 13.1 VGIIa 30.1 17.0 −13.2 non-VGIIb 38.0 29.1 −8.9 non-VGIIc VGIIa
B7467 VGIIa 20.5 37.3 16.8 VGIIa 35.1 20.3 −14.7 non-VGIIb 40.0 30.9 −9.1 non-VGIIc VGIIa
B8555 VGIIa 17.1 31.2 14.1 VGIIa 30.3 17.5 −12.8 non-VGIIb 40.0 27.7 −12.3 non-VGIIc VGIIa
B8577 VGIIa 20.8 36.8 16.0 VGIIa 32.8 20.8 −12.1 non-VGIIb 40.0 31.4 −8.6 non-VGIIc VGIIa
B8793 VGIIa 15.1 29.8 14.7 VGIIa 30.7 18.6 −12.1 non-VGIIb 40.0 29.8 −10.2 non-VGIIc VGIIa
B8849 VGIIa 19.8 34.4 14.6 VGIIa 33.6 20.2 −13.4 non-VGIIb 40.0 30.6 −9.4 non-VGIIc VGIIa
CA-1014 VGIIa 13.1 27.3 14.2 VGIIa 27.0 14.0 −13.0 non-VGIIb 34.9 24.2 −10.7 non-VGIIc VGIIa
CBS-7750 VGIIa 21.8 32.2 10.4 VGIIa 33.4 21.5 −11.9 non-VGIIb 40.0 34.1 −5.9 non-VGIIc VGIIa
ICB-107 VGIIa 21.8 33.6 11.8 VGIIa 33.2 21.2 −12.0 non-VGIIb 40.0 33.8 −6.2 non-VGIIc VGIIa
NIH-444 VGIIa 14.8 27.3 12.5 VGIIa 28.5 15.3 −13.1 non-VGIIb 36.1 25.7 −10.3 non-VGIIc VGIIa
B8508 VGIIa 17.0 27.8 10.8 VGIIa 26.5 17.3 −9.2 non-VGIIb 31.7 22.7 −9.1 non-VGIIc VGIIa
B8512 VGIIa 17.6 28.1 10.4 VGIIa 26.3 18.0 −8.3 non-VGIIb 33.2 24.2 −9.0 non-VGIIc VGIIa
B8558 VGIIa 16.3 24.8 8.5 VGIIa 27.3 15.3 −12.0 non-VGIIb 29.4 20.0 −9.4 non-VGIIc VGIIa
B8561 VGIIa 15.8 27.5 11.8 VGIIa 25.0 16.9 −8.1 non-VGIIb 33.4 23.2 −10.2 non-VGIIc VGIIa
B8563 VGIIa 14.5 27.3 12.8 VGIIa 23.9 15.6 −8.3 non-VGIIb 31.7 21.7 −10.0 non-VGIIc VGIIa
B8567 VGIIa 15.0 36.2 21.2 VGIIa 24.5 16.0 −8.5 non-VGIIb 31.8 22.2 −9.5 non-VGIIc VGIIa
B8854 VGIIa 14.7 26.7 12.0 VGIIa 24.1 15.1 −9.0 non-VGIIb 31.4 22.2 −9.2 non-VGIIc VGIIa
B8889 VGIIa 17.0 28.1 11.0 VGIIa 25.9 17.3 −8.7 non-VGIIb 33.2 23.8 −9.4 non-VGIIc VGIIa
B9077 VGIIa 16.7 27.8 11.1 VGIIa 25.6 16.7 −9.0 non-VGIIb 32.9 24.4 −8.4 non-VGIIc VGIIa
B9296 VGIIa 17.0 27.5 10.5 VGIIa 25.5 17.3 −8.2 non-VGIIb 32.9 24.8 −8.1 non-VGIIc VGIIa
B7394 VGIIb 40.0 19.0 −21.0 non-VGIIa 17.3 29.6 12.3 VGIIb 40.0 29.0 −11.0 non-VGIIc VGIIb
B7735 VGIIb 31.0 18.3 −12.8 non-VGIIa 18.7 31.3 12.6 VGIIb 38.1 28.9 −9.3 non-VGIIc VGIIb
B8554 VGIIb 32.9 21.2 −11.7 non-VGIIa 22.2 35.0 12.8 VGIIb 40.0 30.4 −9.6 non-VGIIc VGIIb
B8828 VGIIb 31.9 21.1 −10.8 non-VGIIa 19.9 35.1 15.2 VGIIb 40.0 30.5 −9.5 non-VGIIc VGIIb
B8211 VGIIb 27.8 16.9 −10.9 non-VGIIa 17.4 28.8 11.4 VGIIb 32.3 22.3 −10.0 non-VGIIc VGIIb
B8966 VGIIb 26.2 14.7 −11.5 non-VGIIa 16.3 24.1 7.9 VGIIb 31.8 23.2 −8.6 non-VGIIc VGIIb
B9076 VGIIb 30.0 18.8 −11.2 non-VGIIa 19.7 30.9 11.4 VGIIb 39.1 27.0 −12.1 non-VGIIc VGIIb
B9157 VGIIb 29.1 16.6 −12.4 non-VGIIa 15.4 23.8 8.5 VGIIb 30.3 21.3 −9.0 non-VGIIc VGIIb
B9170 VGIIb 26.6 15.4 −11.2 non-VGIIa 16.9 24.8 7.9 VGIIb 31.0 22.7 −8.3 non-VGIIc VGIIb


















Table 5 VGII subtyping SYBR MAMA Ct values and genotype assignments for VGIIa,b,c (Continued)
B9290 VGIIb 26.1 13.8 −12.3 non-VGIIa 15.1 24.5 9.5 VGIIb 30.6 21.2 −9.5 non-VGIIc VGIIb
B9241 VGIIb 26.7 20.2 −6.5 non-VGIIa 14.5 24.0 9.4 VGIIb 30.5 21.4 −9.1 non-VGIIc VGIIb
B9428 VGIIb 27.5 14.8 −12.6 non-VGIIa 16.0 24.3 8.2 VGIIb 32.0 22.4 −9.6 non-VGIIc VGIIb
B6863 VGIIc 31.9 20.3 −11.5 non-VGIIa 33.4 20.2 −13.2 non-VGIIb 27.5 40.0 12.5 VGIIc VGIIc
B7390 VGIIc 32.7 18.9 −13.8 non-VGIIa 31.1 17.9 −13.2 non-VGIIb 25.9 40.0 14.1 VGIIc VGIIc
B7432 VGIIc 40.0 18.5 −21.5 non-VGIIa 30.7 17.6 −13.1 non-VGIIb 25.7 40.0 14.3 VGIIc VGIIc
B7434 VGIIc 27.5 15.5 −12.0 non-VGIIa 28.5 15.4 −13.1 non-VGIIb 23.3 40.0 16.7 VGIIc VGIIc
B7466 VGIIc 31.7 20.8 −10.9 non-VGIIa 33.5 20.6 −12.8 non-VGIIb 28.1 40.0 11.9 VGIIc VGIIc
B7491 VGIIc 28.7 17.4 −11.2 non-VGIIa 30.4 16.9 −13.5 non-VGIIb 24.0 40.0 16.0 VGIIc VGIIc
B7493 VGIIc 28.8 18.3 −10.6 non-VGIIa 31.1 18.0 −13.1 non-VGIIb 25.5 40.0 14.5 VGIIc VGIIc
B7641 VGIIc 29.2 17.2 −12.0 non-VGIIa 30.0 17.2 −12.8 non-VGIIb 24.5 40.0 15.5 VGIIc VGIIc
B7737 VGIIc 32.6 20.1 −12.5 non-VGIIa 30.8 20.5 −10.4 non-VGIIb 28.4 40.0 11.6 VGIIc VGIIc
B7765 VGIIc 32.2 19.3 −12.8 non-VGIIa 32.3 18.9 −13.3 non-VGIIb 27.5 40.0 12.5 VGIIc VGIIc
B8210 VGIIc 29.7 17.6 −12.0 non-VGIIa 30.1 17.4 −12.7 non-VGIIb 25.9 40.0 14.1 VGIIc VGIIc
B8214 VGIIc 30.1 17.5 −12.5 non-VGIIa 30.9 17.5 −13.4 non-VGIIb 26.1 40.0 13.9 VGIIc VGIIc
B8510 VGIIc 29.6 17.5 −12.0 non-VGIIa 31.0 17.3 −13.7 non-VGIIb 24.5 40.0 15.5 VGIIc VGIIc
B8549 VGIIc 29.9 17.7 −12.1 non-VGIIa 31.0 17.8 −13.2 non-VGIIb 24.8 40.0 15.2 VGIIc VGIIc
B8552 VGIIc 29.2 17.1 −12.0 non-VGIIa 30.3 17.2 −13.1 non-VGIIb 24.4 40.0 15.6 VGIIc VGIIc
B8571 VGIIc 33.0 20.3 −12.7 non-VGIIa 32.6 20.2 −12.5 non-VGIIb 28.1 40.0 11.9 VGIIc VGIIc
B8788 VGIIc 29.1 17.3 −11.7 non-VGIIa 30.0 17.2 −12.8 non-VGIIb 25.0 40.0 15.0 VGIIc VGIIc
B8798 VGIIc 36.5 22.8 −13.7 non-VGIIa 34.5 22.2 −12.3 non-VGIIb 31.0 40.0 9.0 VGIIc VGIIc
B8821 VGIIc 37.7 24.5 −13.2 non-VGIIa 37.1 24.4 −12.7 non-VGIIb 33.0 40.0 7.0 VGIIc VGIIc
B8825 VGIIc 29.6 17.7 −11.9 non-VGIIa 30.6 17.7 −12.9 non-VGIIb 25.8 40.0 14.2 VGIIc VGIIc
B8833 VGIIc 29.0 17.0 −12.0 non-VGIIa 30.1 17.0 −13.1 non-VGIIb 25.2 40.0 14.8 VGIIc VGIIc
B8838 VGIIc 32.0 19.5 −12.5 non-VGIIa 32.9 19.3 −13.7 non-VGIIb 28.7 40.0 11.3 VGIIc VGIIc
B8843 VGIIc 32.4 19.9 −12.5 non-VGIIa 33.0 19.5 −13.5 non-VGIIb 28.6 40.0 11.4 VGIIc VGIIc
B8853 VGIIc 32.8 21.5 −11.3 non-VGIIa 36.0 23.4 −12.6 non-VGIIb 33.1 40.0 6.9 VGIIc VGIIc
B9159 VGIIc 27.4 20.3 −7.1 non-VGIIa 25.8 16.7 −9.1 non-VGIIb 20.5 34.5 14.0 VGIIc VGIIc
B9227 VGIIc 25.6 13.6 −12.0 non-VGIIa 23.9 14.9 −9.0 non-VGIIb 18.0 31.5 13.4 VGIIc VGIIc
B9235 VGIIc 25.9 13.7 −12.1 non-VGIIa 24.1 14.9 −9.2 non-VGIIb 18.4 32.4 14.0 VGIIc VGIIc
B9244 VGIIc 27.2 19.1 −8.1 non-VGIIa 26.2 16.9 −9.2 non-VGIIb 20.2 32.5 12.3 VGIIc VGIIc
B9245 VGIIc 28.4 22.9 −5.5 non-VGIIa 25.2 17.4 −7.8 non-VGIIb 20.7 34.5 13.8 VGIIc VGIIc
B9295 VGIIc 21.0 17.1 −3.8 non-VGIIa 26.0 19.6 −6.4 non-VGIIb 22.1 28.1 5.9 VGIIc VGIIc
B9302 VGIIc 26.7 15.6 −11.1 non-VGIIa 23.7 15.4 −8.3 non-VGIIb 19.4 34.3 15.0 VGIIc VGIIc


















Table 7 Lower limit dynamic range for MLST and
subtyping MAMA primer sets
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Initial validation revealed the assay panel was 100% sen-
sitive; each assay appropriately identified the known iso-
late genotypes. The ΔCt values for our validation panel
confirmed the stringent threshold ΔCt = 3.3 sufficient to
discriminate the genotypes. In addition, the assay panel
was 100% specific; no cross reactivity occurred between
assays and non-matching genotypes. Further validation of
the assay panel with additional strains revealed 100% sen-
sitivity and specificity. A total of 112 strains were screened
across the MLST assay panel and 100% sensitivity and spe-
cificity was observed (Table 4). A total of 68 previously
genotyped strains were screened across the VGII sub-
typing assay panel with 100% sensitivity and specificity
(Table 5). The assay coefficients of variation ranged from
0.22% to 4.33% indicating high assay repeatability and re-
producibility within and between runs (Table 6). The assays
were designed for genotyping of DNA from known C. gattii
isolates, and are not validated for application to clinical
specimens; they were able to detect DNA concentrations as
low as 0.5 pg/μl (Table 7).Discussion
C. gattii is an emerging pathogen in the US Pacific
Northwest and British Columbia. Molecular and epidemio-
logical investigations revealed the Vancouver Island, BC
outbreak was attributed to a novel and seemingly hypervir-
ulent VGIIa genotype [7,20,22]; moreover, the recent PNW
outbreak was attributed to an additional novel genotype,
VGIIc [23]. These apparent new genotypes (VGIIa and
VGIIc), are responsible for greater than 90% of C. gattii
infections in the BC/PNW region [7]. Given the increased
virulence, varying antifungal susceptibilities and clinical
outcomes caused by these genotypes, as compared to
other C. gattii genotypes, it will be useful to conduct regu-
lar genotyping of C. gattii isolates for both clinical and
epidemiological response purposes [5,7,9,16].Table 6 Interassay and Intraassay for MLST and
Subtyping MAMA







VGIIc 1.61 0.32We have developed a MAMA real-time PCR panel for
cost-efficient and rapid genotyping of C. gattii molecular
types (I-IV) and VGII subtypes (a-c) as a means to better
understand genotype distribution of C. gattii in North
America. To validate the assays, we screened DNA from
a diverse North American and international isolate col-
lection of C. gattii isolates from human, environmental,
and animal sources. All DNA had been previously typed
by MLST. The assay panel performed with 100% sensitivity
and specificity and was 100% concordant with MLST re-
sults. The VGII subtype specific assays may be more per-
tinent to the North American public health and medical
communities; the molecular type (I-IV) specific assays will
be useful for both North American and global genotyping.
The assay is designed for screening in a cost-effective, step-
wise manner. The molecular type-specific assays should be
performed first on all isolates. In North America, the VGIV
assay can be withheld for the first screen, as isolates of
this molecular type have not yet been isolated from North
America. For those North American isolates that are VGII
by molecular type, the subtype-specific assays should be
performed for typing VGIIa, VGIIb, or VGIIc. As we fur-
ther our understanding of C. gattii populations around
the world and their genotype-phenotype relationships,
additional subtype specific assays can be similarly devel-
oped for local and global research purposes.Conclusions
These PCR-based assays are an affordable, efficient, and
sensitive means of genotyping C. gattii isolates. Both the
assay methods and results can be easily transferred among
laboratories. Assay results are based on real-time PCR
cycle threshold values and are therefore objective and
Kelley et al. BMC Microbiology 2014, 14:125 Page 14 of 15
http://www.biomedcentral.com/1471-2180/14/125straightforward for local analysis. The assay panel pre-
sented here is a useful tool for conducting large-scale
molecular epidemiological studies by public health and
research laboratories.
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